Activation of RAS family members confers resistance to ROS1 targeting drugs

The ROS1 tyrosine kinase is activated in lung cancer as a consequence of chromosomal rearrangement. Although high response rates and disease control have been observed in lung cancer patients bearing rearranged ROS1 tumors (ROS1+) treated with the kinase inhibitor crizotinib, many of these patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Cargnelutti, Marilisa, Corso, Simona, Pergolizzi, Margherita, Mévellec, Laurence, Aisner, Dara L., Dziadziuszko, Rafal, Varella-Garcia, Marileila, Comoglio, Paolo M., Doebele, Robert C., Vialard, Jorge, Giordano, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467141/
https://www.ncbi.nlm.nih.gov/pubmed/25691052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467141/
https://www.ncbi.nlm.nih.gov/pubmed/25691052

Ejemplares similares